Cholesterol management in high-risk patients without heart disease

Postgraduate Medicine

Volumn 104, Issue 5, 1998, Pages 117-129

  Grundy, Scott M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CERVISTATIN; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PREVALITE; SIMVASTATIN; UNCLASSIFIED DRUG;

AGING; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FAMILY HISTORY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; RISK FACTOR; TREATMENT INDICATION;

EID: 0031727738     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1998.11.405     Document Type: Article

References (21)

1. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89(3):1333-445
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9
3. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335(14):1001-9
4. Smith SC Jr, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92(1):2-4
5. Pearson T, Rapaport E, Criqui M, et al. Optimal risk factor management in the patient after coronary revascularization: a statement for healthcare professionals from an American Heart Association writing group. Circulation 1994;90(6):3125-33
6. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997;95(6):1683-5
7. Downs JR, Clearfield M, Weis S, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS) Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279(20): 1615-22
8. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Lowering cholesterol in high-risk individuals and populations. New York: Dekker, 1995:33-7
9. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333(20):1301-7
10. American Diabetes Association. Detection and management of lipid disorders in diabetes: consensus statement. Diabetes Care 1996;19(suppl 1):S96-102
11. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21(1):179-82
12. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20(4):614-20 [Erratum, Diabetes Care 1997;20(6):1048]
13. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318(2):81-6
14. Working Group on Management of Patients with Hypertension and High Blood Cholesterol; National High Blood Pressure Education Program; National Cholesterol Education Program (US). Working Group report on management of patients with hypertension and high blood cholesterol. Bethesda: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1990:1; NIH publication No. 90-2361
15. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high-density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994;91(20):9607-11
16. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260(13):1917-21
17. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. (Editorial) Circulation 1997;95(1):1-4
18. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 1994; 154(1):73-82
19. Mostaza J, Vega GL, Snell P, et al. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. J Intern Med 1998;243(4):265-74
20. Newman AB, Siscovick DS, Manolio TA, et al, for the Cardiovascular Heart Study (CHS) Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993; 88(3):837-45
21. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. Circulation 1995;91(5):1472-9